Does UnitedHealthcare Cover Dayvigo (Lemborexant)? Formulary, PA, and Appeal Guide

Dayvigo (lemborexant) is an oral dual orexin receptor antagonist (DORA) that the FDA approved to treat insomnia in adults. While lemborexant and suvorexant (Belsomra) represent the only two FDA-approved DORAs and are frequently discussed alongside one another, they are distinct medications that may sometimes appear in equivalent insurance coverage categories.

UnitedHealthcare commercial and Medicare Advantage plans generally include Dayvigo on their formularies, but coverage is not automatic. Most UHC plans place it on a non-preferred or preferred brand tier and require prior authorization, and many require documented use of a lower-cost sleep medication first. The exact tier, copay, and prior authorization criteria differ by specific plan and change at each annual formulary update, so the only reliable source for your situation is your plan's current Summary of Benefits or the UHC formulary lookup tool (checked as of 2026). This article explains the general pattern UHC plans follow and what to do if a request is denied.

What is established versus what varies by plan

Established: Dayvigo is FDA-approved for insomnia in adults, is a Schedule IV controlled substance, and is commonly subject to prior authorization and step therapy across large commercial payers, UnitedHealthcare included. Appeal rights for denied prior authorizations, including internal appeals and external independent review, are guaranteed by federal law for ACA-governed commercial plans, and by separate, faster timelines for Medicare Part D and Medicare Advantage.

Plan-dependent and unverified without your documents: the specific formulary tier, the dollar copay or coinsurance percentage, which generic agents satisfy step therapy, and internal turnaround-time targets. These details are set by each employer group or plan and are revised annually. Any number quoted for these items should be treated as illustrative, not a guarantee, until confirmed against your plan documents.

Not established from public sources: a documented UHC-specific PA approval rate, an official UHC list of qualifying step-therapy agents, or a published UHC-specific PA turnaround time for Dayvigo. Where the source material for this article referenced these figures, they could not be verified against a primary UHC policy document and have been removed or reframed below.

Formulary placement and cost

Manufacturer-published pricing states Dayvigo carries a list price in the range of a few hundred dollars per month before insurance; discount and manufacturer programs can reduce cash-pay cost substantially. Because list prices and discount-program terms change, check the manufacturer's Dayvigo website for current figures before making a decision based on price.

On UHC commercial formularies, brand-name insomnia medications like Dayvigo typically sit on a preferred or non-preferred brand tier, which usually carries a higher copay than generic tiers. Whether Dayvigo lands on the preferred or non-preferred tier, and what the copay or coinsurance actually is, depends on your specific plan design. Confirm tier and cost-sharing through the UHC member portal or by calling the number on your insurance card, since formulary tiers are revisited annually and can shift without individual notice.

Suvorexant (Belsomra), the other approved DORA, is sometimes placed on a different tier than lemborexant. If your plan prefers one DORA over the other, a formulary exception request that cites your clinical response, tolerability, or contraindication to the preferred agent is the standard mechanism to ask for coverage of the non-preferred one.

Prior authorization: what documentation typically helps

Most UHC commercial and Medicare Advantage plans require prior authorization before covering Dayvigo. While the precise checklist is plan-specific, PA requests for insomnia medications generally go more smoothly when the prescriber's documentation includes:

1. A documented insomnia diagnosis, including symptom duration and frequency consistent with standard diagnostic criteria for chronic insomnia disorder.
2. Whether cognitive behavioral therapy for insomnia (CBT-I) was considered or tried. Clinical guidelines from the American Academy of Sleep Medicine identify CBT-I as a first-line treatment, and payers increasingly ask whether it was addressed before a pharmacologic option is approved. (Verification of the exact guideline citation is recommended before quoting it to a payer.)
3. A record of prior generic sleep medication trials, including drug name, dose, duration, and reason for discontinuation.
4. Any specific safety concerns that make a first-line generic agent inappropriate, such as a history of complex sleep behaviors, falls, or substance use disorder.

Federal and state rules generally require insurers to decide urgent (expedited) prior authorization requests faster than standard ones, but the specific number of hours or days is set by state law and by CMS regulation for Medicare plans rather than by a single nationwide UHC standard. Ask the prescriber's office or UHC member services for the applicable timeframe for your plan type before assuming a specific turnaround.

Step therapy: what "trying something first" usually means

Step therapy requirements ask that a patient try one or more lower-cost generic insomnia medications, and either respond inadequately or have a documented reason not to use them, before Dayvigo is approved. Commonly required first-step agents across payers include generic zolpidem, generic eszopiclone, and sometimes trazodone, though the specific list is set by each plan's formulary and is not standardized across all UHC products.

Clinical trial evidence offers a general comparison point relevant to a step-therapy override argument: a phase 3 randomized trial in adults aged 55 and older (commonly referred to as SUNRISE-1) compared lemborexant against placebo and extended-release zolpidem and reported greater improvement on an objective sleep-continuity measure with lemborexant than with zolpidem ER. The exact effect sizes reported in various secondary summaries differ, and readers or prescribers citing this trial in an appeal should pull the original publication rather than relying on a secondhand number.

Step therapy can often be waived when the prescriber documents a specific contraindication or safety concern with the first-step drug class. The FDA has required boxed warning language on certain sedative-hypnotics, including some Z-drugs, describing rare but serious complex sleep behaviors (such as sleepwalking or sleep-driving) associated with these medications; details are available on the FDA Drug Safety and Availability page. A documented history of this kind of event, or a fall risk in an older adult, is the kind of clinical detail that supports a step-therapy exception request.

Appealing a denial

If UnitedHealthcare denies coverage, commercial members generally have the following avenues, though exact deadlines can vary by state and plan type, so confirm the numbers in your denial letter:

• Internal appeal, first level. A written request, typically including a letter of medical necessity from the prescriber, explaining the specific clinical reasons Dayvigo is appropriate for this patient (for example, failure of or contraindication to step-therapy agents, and relevant safety history).
• Internal appeal, second level. If the first appeal is denied, most commercial plans allow a second internal appeal with any new supporting information, such as additional documented drug trials.
• External review. Under the Affordable Care Act, commercial plan members have the right to an independent external review after exhausting internal appeals. The decision from the independent review organization is binding on the insurer. General information on these rights is available through CMS.
• Peer-to-peer review. At most stages, a prescriber can request a direct conversation with a UHC medical director to explain the clinical rationale. This is not a formal appeal level but is often used alongside one, and prescribers report that some denials are reversed at this step when the clinical picture is explained directly.

Members on UnitedHealthcare Medicare Advantage or standalone Part D plans follow a separate, generally faster, CMS-regulated appeals timeline that includes an independent review entity for external review. The applicable deadlines are set out in your plan's denial notice and in CMS Part D appeals guidance; do not assume commercial timelines apply to a Medicare plan.

Medicare Advantage specifics

UHC Medicare Advantage Part D formularies are separately administered from commercial formularies and follow CMS rules. Dayvigo, like most brand-name insomnia drugs, typically requires prior authorization on these formularies and is placed on a mid-to-upper cost-sharing tier, though the exact tier and copay depend on the specific plan.

Manufacturer copay cards, including the Dayvigo Savings Card, cannot be used by patients enrolled in Medicare, Medicaid, or other federal health programs, consistent with general federal anti-kickback rules governing drug manufacturer coupons. Medicare beneficiaries who need help with cost should instead look at the Medicare Part D Extra Help / Low-Income Subsidy program, state pharmaceutical assistance programs, or independent nonprofit copay foundations such as the Patient Access Network Foundation, which periodically funds sleep-disorder medication costs subject to available funding.

Part D redesign changes tied to the Inflation Reduction Act introduced an annual out-of-pocket cap for covered Part D drugs; the cap amount has changed year to year, so confirm the current figure through CMS or your plan materials rather than relying on a number from an earlier year.

Safety information relevant to coverage review

UHC and other payers' clinical reviewers weigh safety data alongside efficacy when deciding a prior authorization or appeal. Points worth including in documentation:

• Dayvigo's FDA label describes somnolence, headache, and abnormal dreams as commonly reported adverse effects in clinical trials, at rates higher than placebo. The label carries a general sedative-hypnotic warning about complex sleep behaviors, though this is not formatted as the boxed warning applied to some Z-drugs; confirm current label language directly with the prescriber or pharmacist, since labels are updated periodically.
• Lemborexant is metabolized through the CYP3A pathway. The FDA label describes dose limitations and contraindications with certain CYP3A inhibitors and inducers. A prescriber managing a patient on interacting medications should consult the current label directly rather than relying on a secondhand interaction magnitude, since exact pharmacokinetic figures vary by study and are easy to misquote.
• Lemborexant is a Schedule IV controlled substance under the Controlled Substances Act, the same schedule as zolpidem and suvorexant, reflecting some potential for misuse at supratherapeutic doses. This classification itself does not typically block insurance coverage but may factor into utilization review, particularly for patients with a documented substance use history.

Decision framework: what to do at each stage of a Dayvigo coverage request

This is a general decision path built from how commercial and Medicare Advantage prior authorization and appeals processes typically work. It does not replace your plan's actual rules, which you should confirm directly.

Step 1, Before prescribing or filling. Check your plan's current formulary tier and PA requirement for Dayvigo through the UHC member portal. If PA is not listed as required, confirm this in writing (screenshot or reference number) before the pharmacy submits the claim, since formulary files can lag behind actual plan rules.

Step 2, If PA is required. Confirm with the prescriber's office that the PA submission includes: diagnosis and symptom duration, whether CBT-I was discussed, and specific prior medication trials with dates and outcomes. Missing documentation, not clinical ineligibility, is the most common reason a first PA request stalls.

Step 3, If step therapy is required and a first-line drug has not been tried. Ask whether a documented contraindication exists (falls risk, prior complex sleep behavior, substance use history). If yes, request a step-therapy exception rather than starting an unnecessary trial of a drug the prescriber does not want to use. If no clear contraindication exists, a documented trial of the required generic, even a brief one with a clear clinical reason for stopping, is usually the fastest path to approval.

Step 4, If denied. Request the specific denial reason in writing. A denial for "insufficient documentation" is resolved differently than a denial for "step therapy not met" or "not medically necessary." Match the appeal letter to the stated reason rather than re-submitting the same information.

Step 5, If the first appeal is denied. Consider a peer-to-peer review request alongside, not instead of, the formal second-level appeal, since the peer-to-peer conversation alone does not preserve appeal deadlines.

Step 6, If internal appeals are exhausted. File for external independent review (commercial plans) or contact the independent review entity (Medicare Advantage/Part D). Track every deadline from the date on the denial letter, since external review windows are shorter than most people expect and missing one can forfeit the right to further review.

Exception worth flagging to a prescriber: if the patient is 65 or older, has a fall history, or has a diagnosed cognitive impairment, note this explicitly in every step of the request. Geriatric-specific guidance generally advises caution with benzodiazepine receptor agonist sleep aids in older adults, which is a clinically relevant reason to seek a DORA like Dayvigo as a first-choice agent rather than a step-therapy fallback, and payers are more likely to grant an exception when this rationale is explicit rather than implied.

When to seek urgent care instead of pursuing coverage steps

None of the coverage or appeal steps above should delay urgent evaluation. Seek prompt medical attention if a sleep medication (any class, including Dayvigo) causes a serious allergic reaction, sleepwalking or sleep-driving with injury risk, severe daytime impairment affecting safety-sensitive activities, or a mental status change. These are clinical safety issues to raise with a prescriber or emergency services directly, separate from the insurance process described above.